Capital Counsel’s GSK GSK Stock Holding History

Capital Counsel’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-6,560	Closed	-$342K	–	128
2015 Q2	$342K	Hold	6,560	–	–	0.02%	102
2015 Q1	$378K	Hold	6,560	–	–	0.02%	99
2014 Q4	$350K	Sell	6,560 -226	-3%	-$12.6K	0.02%	98
2014 Q3	$390K	Hold	6,786	–	–	0.02%	87
2014 Q2	$454K	Hold	6,786	–	–	0.02%	80
2014 Q1	$453K	Hold	6,786	–	–	0.02%	83
2013 Q4	$453K	Sell	6,786 -60	-0.9%	-$3.89K	0.03%	89
2013 Q3	$429K	Buy	6,846 +286	+4%	+$18.4K	0.03%	82
2013 Q2	$410K	Buy	+6,560	New	+$416K	0.02%	84

Other funds holding GSK

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Capital Counsel's GSK Position: Q3 2015 in Review

Capital Counsel sold out of GSK (GSK) in Q3 2015, closing a stake of 6,560 shares — an estimated $342K sold.

Capital Counsel first reported a position in GSK in Q2 2013 and held it in 9 quarters. The position peaked at $454K in Q2 2014. 706 funds tracked by Wall St. Rank hold GSK as of Q3 2015.

Capital Counsel reported no remaining GSK position as of Q3 2015 after selling out during the quarter.
Capital Counsel sold 6,560 GSK shares in Q3 2015, an estimated $342K.
Capital Counsel first reported a position in GSK in Q2 2013 and held it in 9 quarters.
Capital Counsel's GSK position peaked at $454K in Q2 2014.
706 funds tracked by Wall St. Rank held GSK as of Q3 2015.

Based on Capital Counsel's 13F filing for Q3 2015, filed 13 Nov 2015.